A Final Help Guide For Telomerase

15 Of 2868 children born to 2804 mothers have been followed for assessment of growth, development, metabolic and cardiovascular health to 20?years of age16 (figure 1). Measurement approaches at each stage have been reported previously and relevant information is included in the online supplementary methods.13 16�C18 In addition to the recorded absolute levels of cardiovascular risk factors, we characterised individuals based on current clinical guidelines for hypertension19 overweight and obesity20 and according to a calculated global lifetime risk score.14 Criteria are detailed in the online supplementary methods. Figure?1 Flow diagram to demonstrate recruitment and follow-up of participants from birth to age 20 (blue boxes) with measurements performed (red boxes). Comparisons were performed between Telomerase groups stratified by maternal pregnancy hypertension history. Initially, ... Exclusion criteria and missing data Participants were excluded from this analysis if classed as having congenital malformation at birth, if their mother had pre-pregnancy HTN or if maternal HTN status during pregnancy was not documented. Where data was not available at any follow-up point the individual was excluded for that analysis only. Numbers of offspring followed up at each age, and numbers included in this analysis are summarised in online supplementary table S1. Pregnancy HTN and risk at age 20?years To study clinical risk at age 20?years in offspring of mothers with pregnancy HTN, we divided them into those born to mothers who developed de novo onset HTN (>140/90?mm?Hg) after the 20th week of pregnancy, consistent with ISSHP definitions for hypertensive pregnancy,21 and individuals born to a mother who remained normotensive (NT) based on data collected at time of pregnancy. We then performed a case�Ccontrol comparison of differences in risk factor levels at age 20?years, as well as incidence of HTN and overweight or obesity. Maternal HTN severity We then studied whether severity of the pregnancy condition was relevant to risk profile. We divided the HTN group into two: pregnancy-induced hypertension (PIH) and complicated pregnancy hypertension (CompHTN). PIH encompassed all individuals born at term to a mother who developed HTN without proteinuria. CompHTN included all those whose mother had developed proteinuria (>2+ on dipstix or 300?mg on 24?h urinary protein excretion; thus categorised as pre-eclampsia21), or HTN sufficient to result in preterm delivery at less than 37?weeks gestation. Risk factors were compared between NT individuals and PIH, as well as with CompHTN. To determine the independent effect of preterm delivery we additionally compared associations within the separate groups (pre-eclampsia and HTN leading to preterm delivery) as well as between preterm and term NT pregnancies. No effects were evident so results are presented for the combined groups.